Inspire agrees to sell InSite anti-infective

Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).

The product combines a topical 1% azithromycin formulation with InSite's patented ophthalmic drug-delivery system (DuraSite), designed to increase ocular retention of the drug.

Under the agreement, InSite will grant Inspire exclusive rights to market the anti-infective in the United States and Canada. Inspire will make an initial $13 million payment to InSite, with an additional $19 million pending FDA grants regulatory approval. Inspire also will pay a 20% royalty on net sales for the first 2 years and 25% thereafter.